

ONCOLOGIC PET ICD-9 CODES

Indication	Currently Approved ICD-9 Codes (Per Local Medicare Intermediary)	Possible ICD-9 Codes (or Secondary Codes)
Solitary Pulmonary Nodule: Assess Likelihood of Malignancy (G0125)	793.1 Coin lesion of lung	
Lung Cancer: Diagnosis (G0210)	793.1 Coin lesion of lung 162.9 Malignant neoplasm of bronchus and lung, NOS (<i>positive sputum cytology or pleural fluid cytology</i>) 162.0-162.8 (see below for description): use as appropriate if PET findings allow for a definitive diagnosis of malignant neoplasm of trachea, bronchus or lung.	<i>Adjudication will be required; thus, report should clearly document the history and rationale for the study.</i> 196.1 Metastatic disease of lymph nodes, intrathoracic (<i>search for unknown primary</i>) Paraneoplastic syndrome: consult ICD-9 coding manual (or on-line resource) to obtain specific code.
Lung Cancer: Initial Staging (G0211) Lung Cancer: Restaging (G0212)	Malignant neoplasm of trachea, bronchus, and lung: 162.0 Trachea 162.2 Main bronchus 162.3 Upper lobe 162.4 Middle lobe 162.5 Lower lobe 162.8 Other parts of bronchus or lung 162.9 Bronchus and lung, NOS	See codes for metastatic disease (below) (Use only as secondary codes). See codes for follow-up examinations (below) (Use only as secondary codes for restaging studies).

Indication	Currently Approved ICD-9 Codes (Per Local Medicare Intermediary)	Possible ICD-9 Codes (or Secondary Codes)
Colorectal Cancer: Diagnosis (G0213)	It is expected that PET will rarely be used for diagnosis of colorectal cancer. 153.0-154.1 (see below for description): use as appropriate if PET findings allow for a definitive diagnosis of malignant neoplasm of colon or rectum.	<i>Adjudication will be required; thus, report should clearly document the history and rationale for the study.</i> 211.3 Familial polyposis syndrome 555.9 Regional enteritis, NOS 556.9 Chronic ulcerative colitis, NOS
Colorectal Cancer: Initial Staging (G0214) Colorectal Cancer: Restaging (G0215)	Malignant neoplasm of colon: 153.0 Hepatic flexure 153.1 Transverse colon 153.2 Descending colon 153.3 Sigmoid colon 153.4 Cecum 153.5 Appendix 153.6 Ascending colon 153.7 Splenic flexure 153.8 Other specified colon sites 153.9 Colon, unspecified Malignant neoplasm of rectum and rectosigmoid junction: 154.0 Rectosigmoid junction 154.1 Rectum	See codes for metastatic disease (below) (Use only as secondary codes). See codes for follow-up examinations (below) (Use only as secondary codes for restaging studies).

Indication	Currently Approved ICD-9 Codes (Per Local Medicare Intermediary)	Possible ICD-9 Codes (or Secondary Codes)
Malignant Melanoma: Diagnosis (G0216)	It is expected that PET will rarely be used for diagnosis of malignant melanoma. 172.0-172.9 (see below for description): use as appropriate if PET findings allow for a definitive diagnosis of malignant melanoma.	<i>Adjudication will be required; thus, report should clearly document the history and rationale for the study.</i> See codes for metastatic disease (below) (<i>search for unknown primary</i>).
Malignant Melanoma: Initial Staging (G0217) Malignant Melanoma: Restaging (G0218)	Malignant melanoma of skin: 172.0 Lip 172.1 Eyelid 172.2 Ear 172.3 Other face 172.4 Scalp and neck 172.5 Trunk 172.6 Upper extremity 172.7 Lower extremity 172.8 Other specified sites of skin 172.9 NOS	See codes for metastatic disease (below) (Use only as secondary codes). See codes for follow-up examinations (below) (Use only as secondary codes for restaging studies).

Indication	Currently Approved ICD-9 Codes (Per Local Medicare Intermediary)	Possible ICD-9 Codes (or Secondary Codes)
Lymphoma: Diagnosis (G0220)	It is expected that PET will rarely be used for diagnosis of lymphoma. 202.9X (see below for description): use as appropriate if PET findings allow for a definitive diagnosis of lymphoma.	<i>Adjudication will be required; thus, report should clearly document the history and rationale for the study.</i> Paraneoplastic syndrome: consult ICD-9 coding manual (or on-line resource) to obtain specific code.
Lymphoma: Initial Staging (G0221) Lymphoma: Restaging (G0222)	Hodgkin's Disease: 201.4X Lymphocyte predominance 201.5X Nodular sclerosis 201.6X Mixed cellularity 201.7X Lymphocyte depletion 201.9X Unspecified Non-Hodgkin's Lymphoma: 202.0X Follicular (nodular)-all variants 202.8X Diffuse or mixed small and large cell 200.0X Large cell, cleaved or non-cleaved (histiocytic) 200.1X Small cleaved cell, small lymphocytic, prolymphocytic, small non-cleaved, or lymphoblastic 200.8 X Lymphoplasmacytoid (Waldenstrom's) 200.2X Burkitt 202.1X Mycosis fungoides 202.2X Sezary syndrome 202.3X Malignant histiocytosis 202.4X Leukemic reticuloendotheliosis 202.5X Letterer-Siwe disease 202.6X Malignant mast cell tumors 202.8X Other lymphomas 202.9X Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue Specify site by X as follows; 0 = unspecified extranodal or organ site; 1 = cervical nodes; 2 = thoracic nodes; 3 = abdominal nodes; 4 = axillary/UE nodes; 5 = inguinal/LE nodes; 6 = pelvic nodes; 7 = spleen; 8 = multiple nodal sites	See codes for metastatic disease (below) (Use only as secondary codes). See codes for follow-up examinations (below) (Use only as secondary codes for restaging studies).

Indication	Currently Approved ICD-9 Codes (Per Local Medicare Intermediary)	Possible ICD-9 Codes (or Secondary Codes)
Head and Neck Cancer (Excluding Brain and Thyroid Cancer): Diagnosis (G0223)	196.0 Metastatic disease of lymph nodes, head, face, and neck <i>(search for unknown primary)</i>	
Head and Neck Cancer (Excluding Brain and Thyroid Cancer): Initial Staging (G0224)	Malignant neoplasm of lip: 140.0 Upper lip, vermilion border 140.1 Lower lip, vermilion border 140.3 Upper lip, inner aspect 140.4 Lower lip, inner aspect 140.5 Lip, NOS, inner aspect 140.6 Commissure of lip 140.8 Other sites of lip 140.9 Lip, NOS, vermilion border	See codes for metastatic disease (below) (Use only as secondary codes). See codes for follow-up examinations (below) (Use only as secondary codes for restaging studies).
Head and Neck Cancer (Excluding Brain and Thyroid Cancer): Restaging (G0225)	Malignant neoplasm of tongue: 141.0 Base of tongue 141.1 Dorsal surface of tongue 141.2 Tip and lateral border of tongue 141.3 Ventral surface of tongue 141.4 Anterior two-thirds of tongue, part unspecified 141.5 Junctional zone 141.6 Lingual tonsil 141.8 Other sites of tongue 141.9 Tongue, NOS Malignant neoplasm of major salivary glands: 142.0 Parotid gland 142.1 Submandibular gland 142.2 Sublingual gland 142.8 Other major salivary glands 142.9 Salivary gland, NOS Malignant neoplasm of gum: 143.0 Upper gum 143.1 Lower gum 143.8 Other sites of gum 143.9 Gum, NOS Malignant neoplasm of floor of mouth: 144.0 Anterior portion 144.1 Lateral portion 144.8 Other sites of floor of mouth 144.9 Floor of mouth, part NOS Malignant neoplasm of other and unspecified parts of mouth: 145.0 Cheek mucosa	***** Currently Approved ICD-9 Codes (continued) 145.1 Vestibule of mouth 145.2 Hard palate 145.3 Soft palate 145.4 Uvula 145.5 Palate, NOS 145.6 Retromolar area 145.8 Other specified parts of mouth 145.9 Mouth, NOS Malignant neoplasm of oropharynx: 146.0 Tonsil 146.1 Tonsillar fossa 146.2 Tonsillar pillars (anterior or posterior) 146.3 Vallecule 146.4 Anterior aspect of epiglottis 146.5 Junctional region 146.6 Lateral wall of oropharynx 146.7 Posterior wall of oropharynx 146.8 Other specified sites of oropharynx 146.9 Oropharynx, NOS Malignant neoplasm of nasopharynx: 147.0 Superior wall 147.1 Posterior wall 147.2 Lateral wall 147.3 Anterior wall 147.8 Other specified sites of nasopharynx 147.9 Nasopharynx, NOS

Indication (continued)	Currently Approved ICD-9 Codes (continued)	Currently Approved ICD-9 Codes (continued)
<p>Head and Neck Cancer (Excluding Brain and Thyroid Cancer): Initial Staging (G0224)</p> <p>Head and Neck Cancer (Excluding Brain and Thyroid Cancer): Restaging (G0225)</p>	<p>Malignant neoplasm of hypopharynx:</p> <p>148.0 Postcricoid region</p> <p>148.1 Pyriform sinus</p> <p>148.2 Aryepiglottic fold, hypopharyngeal aspect</p> <p>148.3 Posterior hypopharyngeal wall</p> <p>148.8 Other specified sites of hypopharynx</p> <p>148.9 Hypopharynx, NOS</p> <p>Malignant neoplasm of other and ill-defined sites within the lip, oral cavity, and pharynx:</p> <p>149.0 Pharynx, NOS</p> <p>149.1 Waldeyer's ring</p> <p>149.8 Other</p> <p>149.9 Ill-defined</p> <p>Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses:</p> <p>160.0 Nasal cavities</p> <p>160.1 Auditory tube, middle ear, and mastoid air cells</p> <p>160.2 Maxillary sinus</p> <p>160.3 Ethmoidal sinus</p> <p>160.4 Frontal sinus</p> <p>160.5 Sphenoidal sinus</p> <p>160.8 Other</p> <p>160.9 Assesory sinus, NOS</p>	<p>Malignant neoplasm of larynx:</p> <p>161.0 Glottis</p> <p>161.1 Supraglottis</p> <p>161.2 Subglottis</p> <p>161.3 Laryngeal cartilages</p> <p>161.8 Other specified sites of larynx</p> <p>161.9 Larynx, NOS</p> <p>195.0 Malignant neoplasm of head, face, and neck, NOS</p>

Indication	Currently Approved ICD-9 Codes (Per Local Medicare Intermediary)	Possible ICD-9 Codes (or Secondary Codes)
Esophageal Cancer: Diagnosis (G0226)	It is expected that PET will rarely be used for diagnosis of esophageal carcinoma. 150.0-151.0 (see below for description): use as appropriate if PET findings allow for a definitive diagnosis of esophageal carcinoma.	<i>Adjudication will be required; thus, report should clearly document the history and rationale for the study.</i> 530.19 Barrett's Esophagitis
Esophageal Cancer: Initial Staging (G0227) Esophageal Cancer: Restaging (G0228)	Malignant neoplasm of esophagus: 150.0 Cervical 150.1 Thoracic 150.2 Abdominal (use 151.0 for adenocarcinoma) 150.3 Upper third 150.4 Middle third 150.5 Lower third (use 151.0 for adenocarcinoma) 151.0 Adenocarcinoma of gastro- esophageal junction or cardia	See codes for metastatic disease (below) (Use only as secondary codes). See codes for follow-up examinations (below) (Use only as secondary codes for restaging studies).

Indication	Currently Approved ICD-9 Codes (Per Local Medicare Intermediary)	Possible ICD-9 Codes (or Secondary Codes)
<p>Breast Cancer: Staging/ Restaging (G0253) (For detecting distant metastases or locoregional recurrence, or as baseline for monitoring of planned chemotherapy or hormonal therapy)</p> <p>Breast Cancer: Evaluation of Response to Treatment (G0254) (For monitoring of response DURING chemotherapy or hormonal therapy. If study is performed after completion of treatment, use G0253)</p>	<p>Malignant neoplasm of female breast:</p> <p>174.0 Nipple and areola</p> <p>174.1 Central portion</p> <p>174.2 Upper-inner quadrant</p> <p>174.3 Lower-inner quadrant</p> <p>174.4 Upper-outer quadrant</p> <p>174.5 Lower-outer quadrant</p> <p>174.6 Axillary tail</p> <p>174.8 Other specified site</p> <p>174.9 Unspecified</p> <p>Malignant neoplasm of male breast:</p> <p>175.0 Nipple and areola</p> <p>175.9 Other and unspecified site</p> <p>233.0 Carcinoma in situ, breast</p>	

Indication	Currently Approved ICD-9 Codes (Per Local Medicare Intermediary)	Possible ICD-9 Codes (or Secondary Codes)
<p>Thyroid Cancer: Restaging (G0296) (For detecting residual or recurrent disease in patients previously treated by thyroidectomy and I-131 ablation, now with serum thyroglobulin > 10 ng/mL and negative I-131 scintigraphy)</p>	<p>193 Malignant neoplasm of thyroid 237.4 Neoplasm of other and unspecified endocrine gland V10.87 Personal history of malignant neoplasm of thyroid gland</p>	

Secondary Metastatic Disease Codes Use Based on History or PET Findings	Secondary Treatment Codes Use for Restaging Studies
Metastatic disease of: 196.0 Lymph nodes, head, face, and neck 196.1 Lymph nodes, intrathoracic 196.2 Lymph nodes, intra-abdominal 196.3 Lymph nodes, axilla and upper limb 196.5 Lymph nodes, inguinal and lower limb 196.6 Lymph nodes, intrapelvic 196.8 Lymph nodes, multiple sites 197.0 Lung 197.1 Mediastinum 197.2 Pleura 197.4 Small Intestine 197.5 Large intestine and rectum 197.6 Retroperitoneum and peritoneum 197.7 Liver 197.8 Other digestive organs and spleen 198.0 Kidney 198.1 Other urinary organs 198.2 Skin 198.3 Brain and spinal cord 198.4 Other parts of nervous system 198.5 Bone and bone marrow 198.6 Ovary 198.7 Adrenal gland 198.81 Breast 198.82 Genital organs 199.0 Generalized carcinomatosis	Follow-up examination after: V67.00 Surgery V67.1 Radiotherapy V67.2 Chemotherapy V67.6 Combined therapy